Human RCTPubMed ID: 35658024·2022

Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

Jastreboff AM, Aronne LJ, Ahmad NN, et al.

New England Journal of Medicine, 2022 · n = 2539

Key finding

Tirzepatide 15mg resulted in 22.5% mean weight loss, with 62.9% of participants achieving ≥20% weight loss — unprecedented for an approved drug.

Summary

Pivotal Phase 3 RCT showing tirzepatide 15mg produced 22.5% mean weight loss over 72 weeks in adults with obesity, the highest for any approved medication.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

TirzepatideL5

An FDA-approved dual GIP/GLP-1 receptor agonist that has shown the highest weight loss results of any approved medication.

More research on Tirzepatide

Tirzepatide vs Semaglutide Once Weekly for Weight Management (SURMOUNT-5)

New England Journal of Medicine · 2024 · Human RCT

Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2)

The Lancet · 2023 · Human RCT

Tirzepatide for Weight Management after Lifestyle Intervention (SURMOUNT-3)

Nature Medicine · 2023 · Human RCT

SURPASS-4: Tirzepatide Cardiovascular Outcomes Trial

New England Journal of Medicine · 2023 · Human RCT

Tirzepatide Reduces Sleep Apnea Severity in Obesity

Sleep Medicine Reviews · 2023 · Human Pilot